Resveratrol Reduces Fatty Liver Disease in Rats
Author Information
Author(s): Luis Bujanda, Elizabeth Hijona, Mikel Larzabal, Marta Beraza, Pablo Aldazabal, Nerea García-Urkia, Cristina Sarasqueta, Angel Cosme, Belen Irastorza, Alberto González, Juan I Arenas Jr
Primary Institution: Department of Gastroenterology, University of Country Basque, Donostia Hospital, Centro de Investigación Biomédica en Enfermedades Hepáticas y Digestivas (CIBERehd), San Sebastián, Spain
Hypothesis
Does resveratrol decrease hepatic steatosis and related inflammatory markers in an animal model of nonalcoholic fatty liver disease?
Conclusion
Resveratrol decreased the severity of nonalcoholic fatty liver disease in rats, partly through TNF-α inhibition and antioxidant effects.
Supporting Evidence
- Fat deposition was significantly lower in the resveratrol group compared to the steatosis group.
- TNF-α and MDA levels were significantly higher in the steatosis group than in the resveratrol group.
- Resveratrol treatment led to increased antioxidant enzyme levels in the liver.
- Glucose levels were significantly lower in the resveratrol group.
Takeaway
Giving resveratrol to rats helped their livers get better by reducing fat and inflammation.
Methodology
Male Wistar rats were divided into three groups: control, steatosis, and resveratrol, with the latter receiving daily oral resveratrol for four weeks.
Limitations
The study was conducted on rats, which may not fully represent human conditions.
Participant Demographics
Male Wistar CRL: Wi (Han) rats, approximately 225 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website